We Need Your Urgent Help To Sustain This Website And All Our Research And Community Initiatives. Please Help By Donating To Our Cause. Go To The Sponsorship Section.

BREAKING NEWS
Source: Thailand HIV  Jun 21, 2020  1 year ago
HIV: Research From Emory University Shows That New Adjuvant 3M-052 Extends Immunity Against HIV
HIV: Research From Emory University Shows That New Adjuvant 3M-052 Extends Immunity Against HIV
Source: Thailand HIV  Jun 21, 2020  1 year ago
HIV: Immunology researchers from the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV.


 
The research findings are published today in the journal: Science Immunology. https://immunology.sciencemag.org/content/5/48/eabb1025
 
Significantly, in this pre-clinical study that included 90 rhesus monkeys, the researchers showed 3M-052, a new, synthetic small molecule that targets a specific receptor (TLR 7/8), successfully induced vaccine-specific, long-lived bone marrow plasma cells (BM-LLPCs), which are critical for durable immunity. In a striking observation, 3M-052-induced BM-LLPCs were maintained at high numbers for more than one year after vaccination.
 
It must be noted that this prolonged interval is not only feasible in monitoring pre-clinical effectiveness; it is also highly informative in down selecting vaccine candidates.
 
Dr Sudhir Pai Kasturi, Ph.D., an Assistant Professor in the Department of Pathology and Laboratory Medicine and a research Assistant Professor at Yerkes and the EVC, and the first author of the study told Thailand Medical News, "We have known adjuvants are critical immunity-boosting supplements that help improve the effectiveness of vaccines. Until now, however, it has been unclear which class of adjuvants can promote stable and long-lived immunity in nonhuman primate models. Our study provides that information."
 
Dr Rafi Ahmed, Ph.D., director of the Emory Vaccine Center and first author further commented, "The key to a successful vaccine is durability of immune responses. Antibodies provide the first line of defense against pathogens, and antibody levels are maintained by the generation of long-lived plasma cells that reside in bone marrow. Our study identifies an adjuvant that is effective in generating such long-lived plasma cells in bone marrow. This finding has implications for developing successful vaccines against HIV, influenza and, especially important now, COVID-19.”
 
The researchers are planning human clinical trials as early as the first quarter of 2021.

For more about HIV, keep on logging to Thailand Medical News.
 

MOST READ

Feb 05, 2020  2 years ago
Source : Thailand Medical news